Edition:
India

Radius Health Inc (RDUS.OQ)

RDUS.OQ on NASDAQ Stock Exchange Global Market

29.62USD
13 Dec 2017
Change (% chg)

$0.04 (+0.14%)
Prev Close
$29.58
Open
$29.58
Day's High
$30.07
Day's Low
$28.65
Volume
319,461
Avg. Vol
328,990
52-wk High
$49.15
52-wk Low
$24.68

Select another date:

Tue, Nov 28 2017

BRIEF-Point72 Asset Management Reports 5.1 Percent Passive Stake In Radius Health

* POINT72 ASSET MANAGEMENT, L.P REPORTS 5.1 PERCENT PASSIVE STAKE IN RADIUS HEALTH INC AS OF NOVEMBER 24, 2017 - SEC FILING‍​ Source text: (http://bit.ly/2iXLIQS) Further company coverage:

BRIEF-Radius Health reports Q3 loss per share $1.31

* Radius Health Inc reports third quarter 2017 financial and operating results and provides business update

BRIEF-Radius Health receives FDA fast track designation for elacestrant

* Radius health receives fda fast track designation for elacestrant (rad1901)

BRIEF-Radius Health initiates Phase 1 clinical trial of RAD140 for treatment of hormone receptor positive breast cancer

* Radius Health initiates Phase 1 clinical trial of RAD140 for the treatment of hormone receptor positive breast cancer

BRIEF-Radius Health prices $300 mln of 3 pct convertible senior notes due 2024

* Radius Health announces pricing of $300 million of 3.00 percent convertible senior notes due 2024

BRIEF-Radius Health announces proposed public offering of $300 million of convertible senior notes due 2024

* Radius Health - to use net proceeds to support U.S. commercial launch of Tymlos injection, development of its life cycle management activities​ Source text for Eikon: Further company coverage:

BRIEF-Radius Health reports Q2 loss per share $1.58

* Radius Health reports second quarter 2017 financial and operating results and provides business update

BRIEF-Radius Health appoints Jesper Høiland as president and CEO

* Radius Health appoints Jesper Høiland as president and chief executive officer to lead the next stage of growth and value creation as a fully integrated commercial biotech company

BRIEF-Radius Health announces license and development agreement for Abaloparatide-Sc with Teijin Limited in Japan

* Radius Health announces license and development agreement for Abaloparatide-Sc with Teijin Limited in Japan

Select another date: